CareDx Announces Agreement to Acquire Naveris
CareDx, Inc. has announced its agreement to acquire Naveris, a leader in viral-mediated cancer minimal residual disease (MRD) surveillance testing. This acquisition aims to enhance CareDx’s offerings in precision medicine for transplant patients and caregivers.
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito